LivaNova sells medical devices for heart and brain conditions, and it could see stronger demand as more people need these procedures and as it expands in fast-growing markets like China. Newer therapies and a bigger push into software and services could help it charge more and rely less on one-time equipment sales, but rising healthcare cost pressure and shifting treatment preferences could squeeze growth.Read more
Key Takeaways Global demographic trends support device demand, but supply chain issues, reimbursement limits, and concentrated product risk restrain growth and threaten sustained market share. Expansion in digital offerings and emerging markets is challenged by geopolitical risks, innovation demands, and dependency on favorable healthcare spending environments.Read more
Key Takeaways Breakthrough p-HGNS and VNS therapies, paired with favorable reimbursement, position LivaNova for sustained growth, recurring revenues, and market outperformance. Strategic global expansion, operational upgrades, and increased procedure volumes provide strong levers for margin improvement and above-average cash flow.Read more
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova’s aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
